Novartis' Japan unit faces 15-day suspension over trial data manipulation
The Japanese unit of Swiss drug major Novartis (NOVN: VX) is facing suspension following allegations of data manipulation in the results of Diovan (valsartan) clinical trials.
This would be the first time Japanese regulators have imposed such a penalty on a drug company, though its financial regulators have previously used business suspension orders on banks and brokers. Sources close to the matter have said that suspension would last no more than 15 days.
The company replaced its Japanese management staff after employees were accused of manipulating the trial data in favor of blood pressure drug Diovan, and concealing the side-effects associated with leukemia drug Tasigna (nilotinib).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze